Therapy Directory

Fludarabine clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Fludarabine as a study intervention. Browse Fludarabine recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced May 21, 2026, 2:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

803

Shown on this page

Local indexed summaries

803

Local recruiting

180

The trial list below is retrieved from the live ClinicalTrials.gov search API for Fludarabine. Results on this page are currently sorted by Recently updated.

Showing 1–12 of 803 matching trials for Fludarabine.

Indexed local directory records.

Top conditions

Leukemia 109 Lymphoma 91 Myelodysplastic Syndromes 80 Acute Myeloid Leukemia 66 Myelodysplastic Syndrome 54 Acute Lymphoblastic Leukemia 51

Top sponsors

Fred Hutchinson Cancer Center 86 M.D. Anderson Cancer Center 81 National Cancer Institute (NCI) 68 Masonic Cancer Center, University of Minnesota 50 Kite, A Gilead Company 28 City of Hope Medical Center 27

Top locations

Houston, Texas 180 Seattle, Washington 152 New York, New York 136 Boston, Massachusetts 104 Chicago, Illinois 93 Minneapolis, Minnesota 88

Indexed official records

Open in full search

Conditions: Acute Lymphoblastic Leukemia, B-All
Interventions: CD22 CAR-transduced T cells, Cyclophosphamide, Fludarabine; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 3 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Blood Cancer, Dysmyelopoietic Syndromes, Hematological Neoplasms, Hematopoetic Myelodysplasia, Hematopoietic Malignancies, Leukemia, Lymphocytic, Acute, Malignancy, Hematologic, Myeloid Leukemia, Acute, Neoplasms, Hematologic, Neoplasms, Hematopoietic, Nonlymphoblastic Leukemia, Acute
Interventions: Individual Patient TCR-Transduced PBL, TruSight Oncology (TSO) 500, aldesleukin, cyclophosphamide, fludarabine phosphate; Biological · Device · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Large B-cell Lymphoma
Interventions: Cyclophosphamide, Fludarabine, Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™, cemacabtagene ansegedleucel; Drug · Device · Genetic
Lead sponsor: Allogene Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 58
States / cities: Gilbert, Arizona • Hot Springs, Arkansas • Berkeley, California + 47 more

Conditions: Colorectal Cancer, Minimal Residual Disease
Interventions: Cetuximab, Cyclophosphamide, Fludarabine Phosphate, Lymphodepleting Chemotherapy, Rimiducid (AP1903), TROP2-CAR-NK Cells; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Large B-cell Lymphoma, Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma
Interventions: Cyclophosphamide, Fludarabine, Rondecabtagene autoleucel (ronde-cel); Drug
Lead sponsor: Lyell Immunopharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 31
States / cities: Irvine, California • Los Angeles, California • San Diego, California + 26 more

Conditions: Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related, Myelodysplastic Syndrome
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Best Practice, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Busulfan, Chest Radiography, Computed Tomography, Cytarabine, Daunorubicin Hydrochloride, Decitabine and Cedazuridine, Echocardiography Test, Emavusertib, Enasidenib, Epoetin Alfa, Fludarabine, Gemtuzumab Ozogamicin, Gilteritinib, Liposome-encapsulated Daunorubicin-Cytarabine, Luspatercept, Melphalan, Multigated Acquisition Scan, Mutation Carrier Screening, Olutasidenib, Placebo Administration, Positron Emission Tomography, Total-Body Irradiation, Venetoclax; Procedure · Drug · Other + 2 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 335
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 258 more

Conditions: Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent High Grade B-Cell Lymphoma, Recurrent Indolent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Transformed Chronic Lymphocytic Leukemia, Refactory Childhood Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia, Refractory B-Cell Prolymphocytic Leukemia, Refractory Childhood Non-Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory High Grade B-Cell Lymphoma, Refractory Indolent Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Transformed Chronic Lymphocytic Leukemia
Interventions: Anti-CD19/CD20/CD22 CAR T-Cells, Biopsy, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Cyclophosphamide, Echocardiography, Fludarabine Phosphate, Multigated Acquisition Scan, Pheresis; Biological · Procedure · Drug
Lead sponsor: Sumithira Vasu; Other
Eligibility: 2 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 2
States / cities: Columbus, Ohio

Conditions: Acute Myelogenous Leukemia, Refractory AML, Relapsed Adult AML
Interventions: AdaptNK, Cyclophosphamide, Fludarabine, IL-2; Biological · Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2035
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Hematologic Malignancy, Hematopoietic Cell Transplantation, Relapsed Pediatric ALL
Interventions: Anti-Thymocyte Globulin (Rabbit), CliniMACS System, Cyclophosphamide, Filgrastim, Fludarabine, Melphalan, Mesna, Thiotepa; Drug · Device
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2035
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Acute Lymphoblastic Leukemia, Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia
Interventions: CD19-CD22 CAR T cell infusion, Cyclophosphamide, Fludarabine, Mesna; Device · Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Epithelial Ovarian Cancer, Ovarian Cancer, Ovary Neoplasm, Recurrent
Interventions: Cyclophosphamide, Fludarabine, iC9-CAR.B7-H3 T cells; Drug · Biological
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2036
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Triple Negative Breast Cancer
Interventions: Aldesleukin, Anti-HLA-A2/NY-ESO-1 TCR-transduced Autologous T Lymphocytes, Biopsy, Biospecimen Collection, Computed Tomography, Cyclophosphamide, Echocardiography, Fludarabine, Leukapheresis, Magnetic Resonance Imaging, Mammogram, Multigated Acquisition Scan, Ultrasound Imaging; Biological · Procedure · Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

About this Fludarabine clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Fludarabine as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results: Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Fludarabine.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Fludarabine clinical trials

Filter and sort this therapy

Top conditions

Top sponsors

Top locations

Indexed official records

CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT

CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma

CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic Leukemia

Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells

A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer

About this Fludarabine clinical trials directory page